论文部分内容阅读
目的 观察应用国产基因重组干扰素α２ｂ 治疗慢性乙型肝炎后干扰素抗体的产生对疗效的影响。方法 病例组予以国产重组干扰素α２ｂ 治疗，随访治疗前后不同时间干扰素抗体产生及患者转归情况；采用酶联免疫法检测结合抗体（ＢＡ） ，抗病毒中和法检测中和抗体（ＮＡ） 。结果 对照组（正常供血者）均未检出ＢＡ 和ＮＡ；而１２０ 例患者接受干扰素治疗后，９ 例血中检出ＢＡ（８ ％ ），５ 例血中检出ＮＡ（４％ ）。治疗结束时，９ 例ＢＡ 阳性患者中３ 例ＨＢＶ ＤＮＡ 阴转（３３ ％ ），１１１ 例ＢＡ 阴性患者中５６ 例ＨＢＶ ＤＮＡ 阴转（５０％ ）（Ｐ＞ ０－０５） ；５ 例ＮＡ 阳性患者中ＨＢＶ ＤＮＡ 均未阴转（０），１１５ 例ＮＡ 阴性患者中５８ 例ＨＢＶ ＤＮＡ 阴转（５０％ ）（ Ｐ＞０－０５） 。结论 结果未显示干扰素抗体是影响重组干扰素α２ｂ 疗效的主要因素。
Objective To observe the effect of interferon-α antibody on the curative effect of domestic recombinant interferon α2b after chronic hepatitis B treatment. Methods The cases were treated with recombinant interferon α 2b, and the production of interferon and the prognosis of patients were observed before and after the treatment. The binding antibodies (BA) were detected by ELISA and the neutralizing antibodies (NA ). Results BA and NA were not detected in the control group (normal donors). In the 120 patients treated with interferon, 9 (8%) were detected in blood and 4 (4%) in 5 patients. At the end of treatment, 3 of the 9 BA-positive patients had negative HBV DNA (33%) and 56 of 111 BA negative patients (50%) (P> 0-05). Five patients with NA-positive None of the HBV DNA was negative (0), and 58 of 115 NA negative patients were negative (50%) of HBV DNA (P> 0-05). Conclusion The results did not show that interferon antibody is the main factor affecting the efficacy of recombinant interferon α2b.